By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Addex Therapeutics 

12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva      Switzerland
Phone: 41-22-884-1555 Fax: 41-22-884-1556




Company News
Addex Therapeutics (ADXN.SW) Reports Positive Results Of An mGlu5 Receptor Occupancy Study With Dipraglurant In Healthy Volunteers 4/11/2016 9:56:23 AM
Addex Therapeutics (ADXN.SW) Reports Successful Completion Of An mGlu5 Receptor Occupancy Study With Dipraglurant In Healthy Volunteers 3/15/2016 9:35:49 AM
Addex Therapeutics (ADXN.SW) Dipraglurant Shows Highly Statistically Significant Anti-Dyskinetic Effects Following Additional Analysis Of Data From The PD-LID Phase II Proof Of Concept 1/11/2016 8:55:19 AM
Addex Therapeutics (ADXN.SW)' Dipraglurant Receives Orphan Drug Designation From The FDA For Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 1/4/2016 10:44:49 AM
Addex Therapeutics (ADXN.SW) Reports Statistically Significant Positive Interim Data For Dipraglurant In Healthy Volunteer mGlu5 Receptor Occupancy Trial 12/17/2015 10:20:09 AM
Addex Therapeutics (ADXN.SW) And University of Geneva Collaborators Awarded Swiss Grant To Profile Addex TrkB Allosteric Modulators As Neuroprotective Agents 12/15/2015 10:01:09 AM
Addex Therapeutics (ADXN.SW) Scientists Publish New Data Supporting The Potential Of mGlu4 Receptor Positive Allosteric Modulators In Multiple Sclerosis 12/9/2015 9:20:32 AM
Addex Therapeutics (ADXN.SW) Moves R&D Operations To Geneva's Campus Biotech 12/7/2015 11:01:36 AM
Addex Therapeutics (ADXN.SW) ADX71441 Included In The NINDS Anticonvulsant Screening Program 11/25/2015 10:15:51 AM
Addex Therapeutics (ADXN.SW) And CHUV-UNIL Collaborators Awarded Swiss Grant To Advance Addex MGluR7 And MGluR4 Allosteric Modulators For Neurodegenerative And Psychiatric Diseases 11/23/2015 9:48:25 AM